Long-Term Follow-Up of Drug-Eluting Stents When Inserted for On- and Off-Label Indications

American Journal of Cardiology

Volumn 100, Issue 11, 2007, Pages 1619-1624

  Qasim, Asif ^a   Cosgrave, John ^a   Latib, Azeem ^a   Colombo, Antonio ^a  

^a EMO GVM CENTRO CUORE COLUMBUS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; RAPAMYCIN; THIENO[2,3 B]PYRIDINE DERIVATIVE; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; ARTERY GRAFT; ARTICLE; BRACHYTHERAPY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IMPLANTATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; RISK FACTOR; SAFETY; SAPHENOUS VEIN GRAFT; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; THROMBOSIS; TREATMENT INDICATION;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION;

EID: 36248965268     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.07.013     Document Type: Article

References (20)

1. Colombo A., Drzewiecki J., Banning A., Grube E., Hauptmann K., Silber S., Dudek D., Fort S., Schiele F., Zmudka K., Guagliumi G., and Russell M.E. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108 (2003) 788-794
2. Fajadet J., Morice M.C., Bode C., Barragan P., Serruys P.W., Wijns W., Constantini C.R., Guermonprez J.L., Eltchaninoff H., Blanchard D., et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation 111 (2005) 1040-1044
3. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., Molnar F., and Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
4. Stone G.W., Ellis S.G., Cannon L., Mann J.T., Greenberg J.D., Spriggs D., O'Shaughnessy C.D., DeMaio S., Hall P., Popma J.J., Koglin J., and Russell M.E. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 294 (2005) 1215-1223
5. Biondi-Zoccai G.G., Sangiorgi G.M., Antoniucci D., Grube E., Di Mario C., Reimers B., Tamburino C., Agostoni P., Cosgrave J., and Colombo A. Testing prospectively the effectiveness and safety of paclitaxel-eluting stents in over 1000 very high-risk patients: design, baseline characteristics, procedural data and in-hospital outcomes of the multicenter Taxus in Real-life Usage Evaluation (TRUE) Study. Int J Cardiol 117 (2006) 349-354
6. Bavry A.A., Kumbhani D.J., Helton T.J., Borek P.P., Mood G.R., and Bhatt D.L. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119 (2006) 1056-1061
7. Ellis S.G., Colombo A., Grube E., Popma J., Koglin J., Dawkins K.D., and Stone G.W. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol 49 (2007) 1043-1051
8. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., Rickenbacher P., Hunziker P., Mueller C., Jeger R., Bader F., Osswald S., and Kaiser C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
9. Camenzind E., Steg P.G., and Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents. A cause for concern. Circulation 115 (2007) 1440-1455
10. Beohar N., Davidson C.J., Kip K.E., Goodreau L., Vlachos H.A., Meyers S.N., Benzuly K.H., Flaherty J.D., Ricciardi M.J., Bennett C.L., and Williams D.O. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 297 (2007) 1992-2000
11. Lemos P.A., Serruys P.W., van Domburg R.T., Saia F., Arampatzis C.A., Hoye A., Degertekin M., Tanabe K., Daemen J., Liu T.K., et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 109 (2004) 190-195
12. Zahn R., Hamm C.W., Zeymer U., Schneider S., Nienaber C.A., Richardt G., Kelm M., Levenson B., Bonzel T., Tebbe U., et al. "Real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multi-centre German Cypher Registry. Z Kardiol 93 (2004) 287-294
13. Rao S.V., Shaw R.E., Brindis R.G., Klein L.W., Weintraub W.S., and Peterson E.D. On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol 97 (2006) 1478-1481
14. Win H.K., Caldera A.E., Maresh K., Lopez J., Rihal C.S., Parikh M.A., Granada J.F., Marulkar S., Nassif D., Cohen D.J., and Kleiman N.S. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297 (2007) 2001-2009
15. Cutlip D.E., Windecker S., Mehran R., Boam A., Cohen D.J., van Es G.A., Steg P.G., Morel M.A., Mauri L., Vranckx P., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
16. Lefevre T., Louvard Y., Morice M.C., Dumas P., Loubeyre C., Benslimane A., Premchand R.K., Guillard N., and Piechaud J.F. Stenting of bifurcation lesions: classification, treatments, and results. Catheter Cardiovasc Interv 49 (2000) 274-283
17. Tsagalou E., Stancovic G., Iakovou I., Melzi G., Cosgrave J., Ge L., Michev I., Chieffo A., Airoldi F., Carlino M., Montorfano M., and Colombo A. Early outcome of treatment of ostial de novo left anterior descending coronary artery lesions with drug-eluting stents. Am J Cardiol 97 (2006) 187-191
18. Yamashita T., Nishida T., Adamian M.G., Briguori C., Vaghetti M., Corvaja N., Albiero R., Finci L., Di Mario C., Tobis J.M., and Colombo A. Bifurcation lesions: two stents versus one stent--immediate and follow-up results. J Am Coll Cardiol 35 (2000) 1145-1151
19. Hoye A., Tanabe K., Lemos P.A., Aoki J., Saia F., Arampatzis C., Degertekin M., Hofma S.H., Sianos G., McFadden E., et al. Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. J Am Coll Cardiol 43 (2004) 1954-1958
20. Hoye A., Iakovou I., Ge L., van Mieghem C.A., Ong A.T., Cosgrave J., Sangiorgi G.M., Airoldi F., Montorfano M., Michev I., et al. Long-term outcomes after stenting of bifurcation lesions with the "crush" technique: predictors of an adverse outcome. J Am Coll Cardiol 47 (2006) 1949-1958